Erik L. Ridley and Kate Madden Yee

RSNA 2024
GE HealthCare targets precision care, workflow improvements
A new SPECT/CT system and a range of AI technologies aimed at improving operational efficiencies were among the highlights for GE HealthCare at RSNA 2024.
December 5, 2024
GE HealthCare's new Aurora dual-head SPECT/CT scanner. Image courtesy of GE HealthCare.
2022
Canon highlights U.S. subsidiary, new products at RSNA 2022
CHICAGO - Plans for a new U.S. subsidiary and a range of new product launches were among the highlights for Canon Medical Systems at RSNA 2022.
November 29, 2022
2022 11 30 22 59 1769 2022 11 30 Canon Cxdi Elite 20221130222539
Nuclear Medicine
GE leans into improving patient outcomes, healthcare efficiency
CHICAGO - At this year's RSNA meeting, GE Healthcare is focusing on two goals: improving patient outcomes and boosting the efficiency of the healthcare enterprise. Promotion of these themes comes just weeks before GE is set to spin off its healthcare division into a standalone firm to be called GE HealthCare, which it plans to do in January.
November 28, 2022
2021 11 30 16 39 4000 Ge Rsna 2021 400
Breast
Screening mammography sensitivity is improving, study shows
Breast imagers are doing a better job of detecting breast cancer, according to a study published online May 26 in Radiology that evaluated 2.5 million screening mammograms in the U.S. over a nine-year period.
May 26, 2010
Page 1 of 1
Top Stories
Burden of PSMA-expressing prostate cancer before and after treatment with two cycles of Lu-177 PSMA-617. (A and B) Reduction in overall disease burden is evident after treatment. Avidity of patient’s primary prostate tumor and his osseous metastasis shown before (C) and after (D) treatment.
Molecular Imaging
Case report: Pluvicto as a first-line treatment in late-stage prostate cancer
Since 1996, the patient continually declined androgen deprivation therapy, chemotherapy, and local therapy to the prostate gland.
Mri Head
MRI
New brain MRI imaging technique could help identify Alzheimer's
Research Highlighter Res
Radiology Education
Scholarly activity low among residency program directors
Dexa
Digital X-Ray
3D DEXA shows value in patients with prostate cancer
Digital Innovations Shaping the Future of Radiology
Sponsor Content
Digital Innovations Shaping the Future of Radiology
More in Home
Case report: Pluvicto as a first-line treatment in late-stage prostate cancer
Since 1996, the patient continually declined androgen deprivation therapy, chemotherapy, and local therapy to the prostate gland.
September 26, 2025
Burden of PSMA-expressing prostate cancer before and after treatment with two cycles of Lu-177 PSMA-617. (A and B) Reduction in overall disease burden is evident after treatment. Avidity of patient’s primary prostate tumor and his osseous metastasis shown before (C) and after (D) treatment.
New brain MRI imaging technique could help identify Alzheimer's
By Kate Madden Yee
Researchers used 7-tesla MRI to demonstrate how microvessel pulses in the brain's deep white matter increase with age.
September 26, 2025
Mri Head
Scholarly activity low among residency program directors
By Amerigo Allegretto
Study results point toward program directors focusing on administrative responsibilities rather than scholarly activity.
September 26, 2025
Research Highlighter Res
3D DEXA shows value in patients with prostate cancer
By Will Morton
3D DEXA may be a practical and valuable tool for detecting structural bone changes in prostate cancer patients.
September 25, 2025
Dexa
Smith-Bindman unpacks NEJM pediatric CT study
By Kate Madden Yee
In a video interview, the researcher acknowledged CT's importance to patient care but advocated for its appropriate use.
September 25, 2025
Rebecca Smith-Bindman, MD
Women who skip first mammogram more likely to die of breast cancer
By Amerigo Allegretto
Women who do not participate in their first breast cancer screening are 40% more likely to die later from the disease.
September 24, 2025
Mammography Breast Ipad Patient 400
Study finds AI not cost-effective for breast cancer screening
By Amerigo Allegretto
AI is not cost-effective for breast cancer screening, even with reductions in mortality, false-positive cases, and false-negative cases, according to new research.
September 24, 2025
Breast Tomosynthesis Digital 400 (1)
ACS: Cancer survival rates are lower in rural areas
By Kate Madden Yee
The research also reported lower cancer survival rates for Blacks compared to whites, underscoring "disparities in receipt of care."
September 24, 2025
Rural Res
Save power, curb carbon by switching off surplus CT scanners
By Kate Madden Yee
A new study's findings suggest a relatively easy way to "go green" in the radiology suite.
September 23, 2025
Planet Sustainability
Radiologists deem AI x-ray reports clinically acceptable
By Will Morton
There was no evidence of a difference in acceptability between AI- and radiologist-generated reports under a standard criterion.
September 23, 2025
Kara Cxr
ACR CEO talks imaging’s role in spending bill
By Amerigo Allegretto
Dana Smetherman, MD, CEO of the ACR, spoke with AuntMinnie.com about appropriations bills and how imaging may be affected.
September 23, 2025
American Flag Waving 400 (1)
Adding MBI to DBT finds more breast cancers
By Amerigo Allegretto
Adding molecular breast imaging (MBI) to DBT screening leads to more invasive cancers detected in women with dense breasts.
September 23, 2025
Images in a 62-year-old woman who presented for screening. (A) Image from DBT screening (the synthesized 2D mediolateral oblique view of the left breast is shown) at year on was interpreted as negative and showing heterogeneously dense breast. (B) Image from molecular breast imaging screening (mediolateral oblique view) at year one reveals a 0.9-cm non-mass focal area of uptake in the left breast (arrow). (C) Targeted ultrasound scan (transverse image) shows a suspicious mass in the 3-o’clock position of the left breast, 4 cm from the nipple. Ultrasound-guided core biopsy and lumpectomy revealed a 0.9-cm grade 2 invasive ductal carcinoma, an estrogen receptor–negative, progesterone receptor–negative, human epidermal growth factor receptor 2–negative lesion, with two sentinel nodes negative (N0).
Page 1 of 173
Next Page